Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 5/20 | 0.38 |
| ▸ | CES1 | P23141 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 6/20 | 0.33 |
| ▸ | PPARD | Q03181 | 6/20 | 0.33 |
| ▸ | PPARA | Q07869 | 6/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132104 | 0.78 | CES1 (0.41) | CA1CES2CES1TP53MEN1 | |
| SCHEMBL9848119 | 0.77 | TDP1 (0.35) | CA1CA2CES2CES1TP53 | |
| SCHEMBL18421166 | 0.76 | CES1 (0.40) | CA1CES2CES1TP53MEN1 | |
| SCHEMBL727984 | 0.76 | AKR1B1 (0.42) | CES2CES1MEN1KMT2AALDH1A1 | |
| SCHEMBL29229151 | 0.74 | CES2 (0.38) | CA1CES2CES1TP53MEN1 | |
| SCHEMBL8002430 | 0.72 | AKR1B1 (0.39) | CA2CES2CES1MEN1KMT2A | |
| SCHEMBL28559823 | 0.72 | CES1 (0.42) | CA1CES2CES1TP53MEN1 | |
| SCHEMBL11856586 | 0.72 | AKR1B1 (0.39) | CES2CES1MEN1KMT2AALDH1A1 | |
| SCHEMBL7894375 | 0.72 | NAAA (0.37) | CES2CES1TP53MEN1KMT2A | |
| SCHEMBL16667107 | 0.70 | HCAR2 (0.33) | CES1MEN1KMT2AALDH1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6517811-B2 | Diagnosing a mammal for presence of a tumor by administering compounds such as 125-I-(2-piperidinylaminoethyl)-4-iodobenzamide which have an affinity for cell surface sigma receptors | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2003-02-11 | — | — | US | disclosed |
| US-6447748-B1 | Benzamide compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2002-09-10 | — | — | US | disclosed |
| US-20010006619-A1 | Compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2001-07-05 | — | — | US | disclosed |
| US-6015543-A | DIAGNOSIS OF TUMORS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-01-18 | — | — | US | disclosed |
| US-5993777-A | Benzamide compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5911970-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-06-15 | — | — | US | disclosed |
| WO-1996032968-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN CHRISTY S (US) | 1996-10-24 | — | — | WO | disclosed |
| EP-0650372-A4 | COMPOUNDS FOR CANCER IMAGING AND THERAPY. | JOHN CHRISTY S (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0650372-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN, Christy S. (US) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994026314-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN CHRISTY S (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006619-A1 | Compounds for cancer imaging and therapy | SIGMAR1, TMEM97, ADRB3 | CA1 2848/4885CA2 3276/4885CES2 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.